TD Cowen analyst Dan Brennan lowered the firm’s price target on 10x Genomics to $55 from $60 and keeps an Outperform rating on the shares. The firm said despite the 3Q beat and raise, they view the 3Q as mixed, with continued very strong Spatial ramp and upside juxtaposed against weak Single Cell.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TXG: